The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls

AcneT Cells

Frequency of circulating subpopulations of T regulatory cells in patients with hidradenitis suppurativa

J Eur Acad Dermatol Venereol.

Hessam S, Gambichler T, Höxtermann S, Skrygan M, Sand M, Garcovich S, Meyer T, Stockfleth E, Bechara FG

doi: 10.1111/jdv.16071.

COMMENTED

Acne

Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers

J Eur Acad Dermatol Venereol.

Vossen ARJV, van der Zee HH, Davelaar N, Mus AMC, van Doorn MBA, Prens EP

doi: 10.1111/jdv.15354.

Acne

Hidradenitis Suppurativa Odor and Drainage Scale: A Novel Method for Evaluating Odor and Drainage in Patients with Hidradenitis Suppurativa

Br J Dermatol

Machado MO, Lu JD, Brar R, Kirby J, Garg A, Lowes M, Piguet V, Alavi A

doi: 10.1111/bjd.19686

COMMENTED

Acne

Comparative Overall Comorbidity Burden Among Patients With Hidradenitis Suppurativa

JAMA Dermatol.

Reddy S, Strunk A, Garg A

doi: 10.1001/jamadermatol.

Acne

Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial

J Am Acad Dermatol.

Vossen ARJV, van Doorn MBA, van der Zee HH, Prens EP

doi: 10.1016/j.jaad.2018.06.046.

Acne

Assessment of Overall and Specific Cancer Risks in Patients With Hidradenitis Suppurativa

JAMA Dermatol.

Jung JM, Lee KH, Kim YJ, Chang SE, Lee MW, Choi JH, Won CH, Lee WJ

doi: 10.1001/jamadermatol.2020.1422.

AcneRosacea

Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa

J Eur Acad Dermatol Venereol.

Chernyshov PV, Zouboulis CC, Tomas-Aragones L, Jemec GB, Svensson A, Manolache L, Tzellos T, Sampogna F, Pustisek N, van der Zee HH, Marron SE, Spillekom-van Koulil S, Bewley A, Linder D, Abeni D, Szepietowski JC, Augustin M, Finlay AY

doi: 10.1111/jdv.15519.

Acne

Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study

J Am Acad Dermatol.

Zouboulis CC, Okun MM, Prens EP, Gniadecki R, Foley PA, Lynde C, Weisman J, Gu Y, Williams DA, Jemec GBE

doi: 10.1016/j.jaad.2018.05.040.

Acne

Improvement in Hidradenitis Suppurativa and Quality of Life in Patients Treated With Adalimumab: Real-World Results From the HARMONY Study

J Eur Acad Dermatol Venereol

Hafner A, Ghislain PD, Kovács R, Batchelor R, Katoulis AC, Kirby B, Banayan H, Schonbrun M

doi: 10.1111/jdv.17551

Related content

Frequency of circulating subpopulations of T regulatory cells in patients with hidradenitis suppurativa

Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers

Hidradenitis Suppurativa Odor and Drainage Scale: A Novel Method for Evaluating Odor and Drainage in Patients with Hidradenitis Suppurativa

Comparative Overall Comorbidity Burden Among Patients With Hidradenitis Suppurativa

Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial

Assessment of Overall and Specific Cancer Risks in Patients With Hidradenitis Suppurativa

Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa

Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study

Improvement in Hidradenitis Suppurativa and Quality of Life in Patients Treated With Adalimumab: Real-World Results From the HARMONY Study